
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon Inc., a clinical-stage biopharmaceutical company, is developing innovative therapies targeting complement-mediated disorders through its platform technology, which focuses on the crucial role of C1q activation. Positive results from the ANX005 clinical trials, demonstrating a significant improvement in recovery metrics compared to standard therapies and a favorable risk profile, highlight the therapeutic potential and market differentiation of its product pipeline. Additionally, the early completion of Phase 3 enrollment for ANX007, coupled with its recognition in the EMA's PRIME PDC pilot program, underlines the company's commitment to advancing its vision preservation goals, suggesting a robust regulatory pathway for future product approvals.
Bears say
Annexon Inc has faced significant financial challenges, highlighted by a substantial net loss of $49.2 million, or $0.34 per share, indicating pressure on profitability as the company progresses through its clinical trials. The key risks, particularly surrounding the potential failure of its lead product candidate ANX005 in clinical studies and its ability to secure regulatory approvals in both the US and EU, raise concerns over the future viability of its revenue projections and market penetration. Furthermore, uncertainties regarding the ability of ANX005 to achieve peak commercial revenue estimates based on market size and pricing further diminish the outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares